Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.

van Oers M, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Davis J, Banerjee H, Stefanelli T, Hoever P, Geisler C.

Blood Cancer J. 2019 Dec 4;9(12):98. doi: 10.1038/s41408-019-0260-2.

2.

Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.

Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J.

Eur Neuropsychopharmacol. 2014 Aug;24(8):1257-68. doi: 10.1016/j.euroneuro.2014.05.002. Epub 2014 May 13.

PMID:
24880753
3.

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies.

Dingemanse J, Gehin M, Cruz HG, Hoever P.

Drug Des Devel Ther. 2014 Apr 28;8:397-403. doi: 10.2147/DDDT.S62118. eCollection 2014.

4.

Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.

Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J.

CNS Drugs. 2014 Apr;28(4):361-72. doi: 10.1007/s40263-014-0150-x.

PMID:
24627301
5.

Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.

Dingemanse J, Cruz HG, Gehin M, Hoever P.

J Pharm Sci. 2014 May;103(5):1548-56. doi: 10.1002/jps.23916. Epub 2014 Mar 6.

PMID:
24604243
6.

Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist.

Shakeri-Nejad K, Hoch M, Hoever P, Dingemanse J.

Eur J Pharm Sci. 2013 Aug 16;49(5):836-44. doi: 10.1016/j.ejps.2013.06.002. Epub 2013 Jun 11.

PMID:
23770377
7.

Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects.

Dingemanse J, Hoever P.

Drugs R D. 2013 Jun;13(2):145-51. doi: 10.1007/s40268-013-0017-5.

8.

Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects.

Hoever P, Hay J, Rad M, Cavallaro M, van Gerven JM, Dingemanse J.

J Clin Psychopharmacol. 2013 Jun;33(3):363-70. doi: 10.1097/JCP.0b013e31828f5a7a.

PMID:
23609389
9.

Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.

Dingemanse J, Hoever P, Hoch M, Treiber A, Wagner-Redeker W, Miraval T, Hopfgartner G, Shakeri-Nejad K.

Drug Metab Dispos. 2013 May;41(5):1046-59. doi: 10.1124/dmd.112.050120. Epub 2013 Feb 21.

PMID:
23431113
10.

Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.

Hoch M, Hoever P, Theodor R, Dingemanse J.

Eur J Clin Pharmacol. 2013 Jun;69(6):1235-45. doi: 10.1007/s00228-012-1470-8. Epub 2013 Jan 20.

PMID:
23334403
11.

Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.

Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J.

Eur J Clin Pharmacol. 2013 Mar;69(3):523-32. doi: 10.1007/s00228-012-1403-6. Epub 2012 Sep 19.

PMID:
22990330
12.

Orexin receptor antagonism: an ascending multiple-dose study with almorexant.

Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J.

J Psychopharmacol. 2012 Aug;26(8):1071-80. doi: 10.1177/0269881112448946. Epub 2012 Jun 13.

PMID:
22695489
13.

Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.

Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, Dingemanse J.

Eur Neuropsychopharmacol. 2013 Feb;23(2):107-17. doi: 10.1016/j.euroneuro.2012.04.012. Epub 2012 May 30.

PMID:
22658401
14.

Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.

Hoever P, Dorffner G, Beneš H, Penzel T, Danker-Hopfe H, Barbanoj MJ, Pillar G, Saletu B, Polo O, Kunz D, Zeitlhofer J, Berg S, Partinen M, Bassetti CL, Högl B, Ebrahim IO, Holsboer-Trachsler E, Bengtsson H, Peker Y, Hemmeter UM, Chiossi E, Hajak G, Dingemanse J.

Clin Pharmacol Ther. 2012 Jun;91(6):975-85. doi: 10.1038/clpt.2011.370.

15.

Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects.

Hoch M, Hoever P, Zisowsky J, Priestley A, Fleet D, Dingemanse J.

Pharmacology. 2012;89(1-2):53-7. doi: 10.1159/000335367. Epub 2012 Feb 1.

PMID:
22302127
16.

Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects.

Hoch M, Hoever P, Alessi F, Marjason J, Dingemanse J.

Pharmacology. 2011;88(3-4):121-6. doi: 10.1159/000330098. Epub 2011 Aug 25.

PMID:
21865769
17.

Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects.

Hoch M, Hoever P, Haschke M, Krähenbühl S, Dingemanse J.

J Clin Pharmacol. 2011 Jul;51(7):1116-21. doi: 10.1177/0091270010377634. Epub 2010 Sep 17. No abstract available.

PMID:
20852003
18.

Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.

Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, Dingemanse J.

Clin Pharmacol Ther. 2010 May;87(5):593-600. doi: 10.1038/clpt.2010.19. Epub 2010 Apr 7.

PMID:
20376002
19.

Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects.

de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J.

J Psychopharmacol. 2010 Nov;24(11):1619-29. doi: 10.1177/0269881109106898. Epub 2009 Jul 31.

PMID:
19648220
20.

Pseudohallucinations after zolpidem intake: a case report.

de Haas S, Dingemanse J, Hoever P, Cohen A, van Gerven J.

J Clin Psychopharmacol. 2007 Dec;27(6):728-30. No abstract available.

PMID:
18004155
21.

Promotion of sleep by targeting the orexin system in rats, dogs and humans.

Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, Hess P, Qiu C, Buchmann S, Scherz M, Weller T, Fischli W, Clozel M, Jenck F.

Nat Med. 2007 Feb;13(2):150-5. Epub 2007 Jan 28.

PMID:
17259994

Supplemental Content

Loading ...
Support Center